Viridian Therapeutics (STU:1S1) EPS (Basic): €-2.86 (TTM As of Mar. 2026)


STU:1S1 Viridian Therapeutics Inc STU:1S1
60 GF Score
Price €15.70
GF Value €1,489.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Viridian Therapeutics EPS (Basic)?

Viridian Therapeutics STU:1S1 +3.29% 60 EPS (Basic) is €-2.86 as of Mar. 2026. GuruFocus rates STU:1S1 with a GF Score™ of 60/100 and a GF Value™ of €1,489.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

Viridian Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.78. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-2.86.

Viridian Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.78. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-2.86.

Viridian Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was €-0.84. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -2.92.

During the past 3 years, the average EPS without NRI Growth Rate was -7.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 20.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 36.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Viridian Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 70.40% per year. The lowest was -7.00% per year. And the median was 26.10% per year.

Viridian Therapeutics  (STU:1S1) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Viridian Therapeutics EPS (Basic) Related Terms

Viridian Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Viridian Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics EPS (Basic) Chart

Viridian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.89 -2.56 -3.59 -2.93 -2.84

Viridian Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.81 -0.87 -0.29 -0.92 -0.78
STU:1S1
60GF Score
Viridian Therapeutics Inc STU:1S1
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Viridian Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-292.581-0)/84.803
=-3.45

Viridian Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-90.739-0)/102.212
=-0.89

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-2.86 mean?
Viridian Therapeutics (STU:1S1) has a EPS (Basic) of €-2.86 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Viridian Therapeutics and its competitors.
Is Viridian Therapeutics' EPS (Basic) too high?
Viridian Therapeutics' current EPS (Basic) is €-2.86. Overall, Viridian Therapeutics has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' EPS (Basic) compare to SION and NTLA?
Viridian Therapeutics' EPS (Basic) of €-2.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current EPS (Basic) is €-2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Viridian Therapeutics (STU:1S1) is currently considered Possible Value Trap. The stock's GF Value™ is €1,489.40, compared to a current price of €15.70 — trading 98.9% below its estimated fair value. The current EPS (Basic) is €-2.86. Viridian Therapeutics' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Viridian Therapeutics (STU:1S1), the current EPS (Basic) is €-2.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viridian Therapeutics (STU:1S1) Overvalued in 2026?

Based on GuruFocus' analysis, Viridian Therapeutics stock appears to be undervalued. The current stock price of €15.70 is trading 98.9% below its estimated GF Value™ of €1,489.40. GuruFocus considers Viridian Therapeutics to be Possible Value Trap.

Key valuation signals for STU:1S1:

  • EPS (Basic): €-2.86
  • GF Value™: €1,489.40 vs. price of €15.70 (98.9% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the STU:1S1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viridian Therapeutics Business Description

Other Exchanges VRDN:USA0K1R:UK
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
60GF Score

Get the complete analysis for STU:1S1

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.70
Price
€1,489.40
GF Value